country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-143491

Copy Link Print Information

VS 8

VS 8 (Compound VS 8) is a potent, orally active VEGFR-2 inhibitor with significant anti-angiogenic effects. VS 8 induces cancer cell apoptosis and migration. VS 8 is active against CSCs (Cancer stem cells).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2471865-38-8
Formel: C₂₆H₂₀F₃N₃O₃
Molecular Weight:479.45

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (277 KB)

VS 8 Chemical Structure

CAS. Nr.: 2471865-38-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

VEGFR-2

Alle VEGFR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC₅₀	1166 nM Compound: VS8	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by trypan blue assay assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by trypan blue assay assay	[PMID: 33002846]
HepG2	IC₅₀	2201 nM Compound: VS8	Antiproliferative activity against human HepG2 cells harboring CD133+ assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells harboring CD133+ assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
HepG2	IC₅₀	257.8 nM Compound: VS8	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
HepG2	IC₅₀	3290 nM Compound: VS8	Antiproliferative activity against human HepG2 cells harboring CD44+ assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells harboring CD44+ assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
HUVEC	IC₅₀	9643 nM Compound: VS8	Antiproliferative activity against human HUVEC assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HUVEC assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
MCF7	IC₅₀	953.3 nM Compound: VS8	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
MDA-MB-231	IC₅₀	1413 nM Compound: VS8	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
MDA-MB-231	IC₅₀	3577 nM Compound: VS8	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by trypan blue assay assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by trypan blue assay assay	[PMID: 33002846]

In Vitro

VS 8 (Compound VS 8) (0.01-100 µM, 24 h) shows potent anti-proliferative activity against MCF-7, MDA-MB-231, Hep G2, and HUVECs cells^[1].
VS 8 induces early apoptosis in MDA-MB-231 (1413 nM, 72 h), Hep G2 (257.80 nM, 24 h), and HUVECs (1954 nM, 24 h) cells^[1].
VS 8 is shown to be a pro-oxidant molecule that enhances the ROS level in Hep G2 cells^[1].
VS 8 inhibits wound healing and migration of MCF-7 cancer cells^[1].
VS 8 downregulates human vascular endothelial growth factor (hVEGF) and hVEGFR-2 expression in HUVECs^[1].
VS 8 (257.80 nM, 48 h) arrests cell cycle at ‘G0/G1’ and ‘S’ phase in CD44+ and CD133+ CSCs, respectively^[1].
VS 8 inhibits TGF-β-induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma by the upregulation of E-cadherin and the suppression of vimentin and SNAIL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

MCF-7, MDA-MB-231, Hep G2, and HUVECs cells
Concentration:

0.01, 0.1, 1, 10, 50, and 100 µM
Incubation Time:

24 h
Result:

Showed significantly potent anti-proliferative activity against all the selected cell lines in a dose-dependent manner, with IC₅₀ values of 953.30, 1413, 257.80, and 1954 nM against MCF-7, MDA-MB-231, Hep G2, and HUVECs cells.

Apoptosis Analysis^[1]

Cell Line:

MDA-MB-231, Hep G2, and HUVECs cells
Concentration:

1413, 257.80, and 1954 nM for MDA-MB-231, Hep G2, and HUVECs cells, respectively.
Incubation Time:

72 h for MDA-MB-231 cells; 24 h for Hep G2 and HUVECs cells
Result:

Resulted in high population of early apoptotic MDA-MB-231 cells (68.34 ± 0.18%). A significant increase in % apoptotic index (~86.66%) was observed in Hep G2 cells. The percentage of early apoptotic cells were found to be ~37.53% in HUVECs cells.

Cell Cycle Analysis^[1]

Cell Line:

CD44+ and CD133+ CSCs isolated from Hep G2 cells
Concentration:

257.80 nM
Incubation Time:

48 h
Result:

Arrested cell cycle at ‘G0/G1’ and ‘S’ phase in CD44+ and CD133+ CSCs, respectively.

In Vivo

VS 8 inhibits angiogenesis in the chick chorioallantoic membrane without oral toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wistar rats (180-220 gm)^[1]
Dosage:

5 mg/kg
Administration:

Oral administration (Pharmacokinetic Analysis)

Result:

Pharmacokinetic parameters for VS 8 in rats after administration of oral dose (5 mg/ kg) ^[1]

Pharmacokinetic parameters	Unit	Value
C_max	μg/mL	39.7193 ± 0.36
T_max	hrs	6 ± 0
AUC_(0-72)	mg/mL*hrs	621.3236 ± 1.843
AUC_(0-∞)	mg/mL*hrs	625.2219 ± 1.864
AUMC_(0-∞)	(mg/mL*hrs²)	8929.284 ± 72.85
MRT	hrs	14.2817 ± 0.102
t_1/2	hrs	11.9277 ± 0.324

Data represented as mean ± SD (n = 3); t_1/2, Half-Life; C_max, Maximum Observed Concentration; T_max, Maximum Observed Time; AUC, Area Under Curve; AUMC Area Under Movement Curve, MRT, Mean Residence Time.

Chemical Information

CAS. Nr. 2471865-38-8
Molecular Weight 479.45
Formel C₂₆H₂₀F₃N₃O₃
SMILES

CC(NC1=CC=C(OC2=C3C=CC=C(NC(NC4=CC=CC(C(F)(F)F)=C4)=O)C3=CC=C2)C=C1)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Siddharth J Modi, et al. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. Eur J Med C [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Angebot einholen Auf Lager

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

VS 8

Alle VEGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

VS 8 Related Classifications

HY-143491 Related Classifications